Anti-IL-1R1 Polyclonal Antibody is a Rabbit antibody targeting IL-1R1. Anti-IL-1R1 Polyclonal Antibody can be used in FCM, ICC/IF, IF, IHC-Fr, IHC-P, WB.

IgG

Human (predicted:Mouse,Dog,Pig)

1. Paraformaldehyde-fixed, paraffin embedded (human colon carcinoma); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 min; Blocking buffer (normal goat serum) at 37°C for 30 min; Antibody incubation with (IL-1R1) Polyclonal Antibody, Unconjugated (TMAB-00953) at 1:400 overnight at 4°C, followed by operating according to SP Kit (Rabbit) instructionsand DAB staining.
2. HepG2 cell; 4% Paraformaldehyde-fixed; Triton X-100 at room temperature for 20 min; Blocking buffer (normal goat serum) at 37°C for 20 min; Antibody incubation with (IL-1R1) polyclonal Antibody, Unconjugated (TMAB-00953) 1:100, 90 minutes at 37°C; followed by a conjugated Goat Anti-Rabbit IgG antibody at 37°C for 90 minutes, DAPI (blue) was used to stain the cell nucleus.
3. Sample: Hela (human) Cell Lysate at 40 μg
Primary: Anti-IL-1R1 (TMAB-00953) at 1/300 dilution
Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution
Predicted band size: 63 kDa
Observed band size: 63 kDa
4. Blank control (blue line): MCF7 (fixed with 70% methanol overnight at 4°C).
Primary Antibody (green line): Rabbit Anti-IL-1R1 receptor antibody (TMAB-00953), Dilution: 0.2 μg/10^6 cells;
Isotype Control Antibody (orange line): Rabbit IgG.
Secondary Antibody (white blue line): Goat anti-rabbit IgG-PE, Dilution: 1 μg/test.

FCM=1 μg/Test; ICC/IF=1:100-500; IF=1:100-500; IHC-Fr=1:100-500; IHC-P=1:100-500; WB=1:500-2000

Polyclonal

KLH conjugated synthetic peptide: human IL-1R1

Human

IL1R1

Interleukin-1 receptor type 1

Endothelial Cell Markers,Inflammatory mediators,Interleukins,T Lymphocytic Lineage,Dendritic Cell Lineage

Receptor for IL1A, IL1B and IL1RN. After binding to interleukin-1 associates with the corecptor IL1RAP to form the high affinity interleukin-1 receptor complex which mediates interleukin-1-dependent activation of NF-kappa-B, MAPK and other pathways. Signaling involves the recruitment of adapter molecules such as TOLLIP, MYD88, and IRAK1 or IRAK2 via the respective TIR domains of the receptor/coreceptor subunits. Binds ligands with comparable affinity and binding of antagonist IL1RN prevents association with IL1RAP to form a signaling complex.